04-1570
Anti-RNA polymerase II subunit B1 (phospho-CTD Ser-7) Antibody, clone 4E12
clone 4E12, from rat
Synonym(s):
DNA-directed RNA polymerase II A, DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit, DNA-directed RNA polymerase II subunit A, DNA-directed RNA polymerase III largest subunit, RNA polymerase II subunit B1, RNA-directed RNA
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rat
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
4E12, monoclonal
species reactivity
mouse
species reactivity (predicted by homology)
human (based on 100% sequence homology)
technique(s)
ChIP: suitable
ELISA: suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pSer7)
Gene Information
human ... POLR2B(5431)
Related Categories
General description
RNA polymerase II subunit B1 (RPB1) is the largest subunit of the RNA polymerase II complex. As a holoenzyme RNA polymerase II catalyzes transcription of eukaryotic DNA into RNA using the four ribonucleoside triphosphates as substrates. The RBP1 subunit, in combination with other polymerase subunits, forms a large central cleft that maintains contact between the active site of the enzyme, the DNA template, and the nascent RNA transcript. This subunit also contains a carboxy terminal domain (CTD) consisting of tandem heptapeptide repeats. Phosphorylation activates the RNA polymerase II beta subunit, allowing it to serve as an assembly platform for additional subunits that modulate initiation, elongation, termination and mRNA processing. In actively transcribing RNA polymerase ‘Ser-2’ and ‘Ser-5’ of the heptapeptide repeat are phosphorylated. Ser-7 is phosphorylated before initiation of transcription at promoter regions.
Specificity
This antibody recognizes RNA polymerase II subunit B1 at the CTD when phosphorylated at Ser7.
Immunogen
Epitope: Ser7
Ovalbumin-conjugated linear peptide corrresponding to human RNA polymerase subunit B1 CTD phosphorylated at Ser7.
Application
Anti-RNA polymerase II subunit B1 (phospho-CTD Ser-7) Antibody, clone 4E12 is a Rat monoclonal antibody for detection of RNA polymerase II subunit B1 (phospho-CTD Ser-7) has been validated in WB, ELISA.
Chromatin Immunoprecipitation Analysis: A representative lot was used by an independent laboratory in ChIP. (Chapman, R., et al. (2007). Science. 318(5857):1780 -1782.)
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
RNA Metabolism & Binding Proteins
Transcription Factors
RNA Metabolism & Binding Proteins
Quality
Evaluated by Western Blot in γ-PPase untreated and treated NIH/3T3 cell lysates.
Western Blot Analysis: 0.25 µg/ml of this antibody detected RNA polymerase II CTD on 10 µg of γ-PPase untreated and treated NIH/3T3 cell lysates.
Western Blot Analysis: 0.25 µg/ml of this antibody detected RNA polymerase II CTD on 10 µg of γ-PPase untreated and treated NIH/3T3 cell lysates.
Target description
~ 220 kDa
Physical form
Format: Purified
Protein G Purified
Purified rat monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
γ-protein phosphatase (γ-Ppase) untreated and treated NIH/3T3 cell lysates
γ-protein phosphatase (γ-Ppase) untreated and treated NIH/3T3 cell lysates
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Amanda Balboni Iniguez et al.
Cancer cell, 33(2), 202-216 (2018-01-24)
Many cancer types are driven by oncogenic transcription factors that have been difficult to drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers. Through chemical genomics screening, we identified that Ewing sarcoma is a disease with preferential sensitivity
Emily Brookes et al.
Cell stem cell, 10(2), 157-170 (2012-02-07)
Polycomb repressor complexes (PRCs) are important chromatin modifiers fundamentally implicated in pluripotency and cancer. Polycomb silencing in embryonic stem cells (ESCs) can be accompanied by active chromatin and primed RNA polymerase II (RNAPII), but the relationship between PRCs and RNAPII
Huishan Zeng et al.
Cell death & disease, 12(11), 1048-1048 (2021-11-07)
Metastasis is one of most lethal causes that confer a poor prognosis of patients with esophageal squamous cell carcinoma (ESCC), whereas there is no available target drug for metastatic ESCC currently. In this study, we aimed to determine whether the
Kaiwei Liang et al.
Molecular and cellular biology, 35(6), 928-938 (2015-01-07)
Cyclin-dependent kinase 9 (CDK9) and CDK12 have each been demonstrated to phosphorylate the RNA polymerase II C-terminal domain (CTD) at serine 2 of the heptad repeat, both in vitro and in vivo. CDK9, as part of P-TEFb and the super
Mei Zeng et al.
eLife, 7 (2018-11-14)
High-grade serous ovarian cancer is characterized by extensive copy number alterations, among which the amplification of MYC oncogene occurs in nearly half of tumors. We demonstrate that ovarian cancer cells highly depend on MYC for maintaining their oncogenic growth, indicating
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service